The Erganoid-1 Swis Sw iss Medic ical al Unio ion SA - - PowerPoint PPT Presentation

The Erganoid-1™ Improving cancer treatments

Daniil Golubev (CEO) Marion Argi (CMO) Emanuele Pizzatti (CFO)

To the attention of the Ju Jury members of

• f t

the S e Swiss ss In Innovation

• n C

Challen enge ge 24 October 2019

Ta Table of contents

What is Swiss Medical Union The Problems The ineffective traditional approach The criticality of the time to prognosis & treatment Impacts on the healthcare sector The Solution: Erganoid - 1™ Three «Organs» for the «Man-on-the-chip» The «Man-on-the-chip»: the magic Swiss Medical Union approach: USP summary Business model: clinical practice inclusion and R&D Labs The market: definitions The market: data & sales orientation Competitive landscape: by USP Our Team, business advisors and partners

Contacts: Sw Swis iss Medic ical al Unio ion SA CH-550.1.183.498-2 c/o Y-Parc SA Rue Galilée 7 - 1400 Yverdon-les-Bains

InnoSuisse Project – Swiss Innovation Agency Organizational Plan – Key Companies Joint-venture – Optimal scenario Achievements to date Go To Market – Strategic elements Go To Market – Sales orientation Use of funds: key elements & deal info Financials: Expected results and EV Annex I: Bibliography Annex II: Exit strategy Annex III: Exit strategy, strategic acquisition Annex IV: Considerations at scale: Key Financial & strategic metrics 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

What is Swiss Medical Union’s Erganoid

Without Prejudice & Confidential 2

The Er Ergano noid is a medical device - Micro-Bioreactor - able to provide qui quick (7 days) and per performi ming ng ex ex-vi vivo vo tests on human cells to support medics and practitioners in clinical decisions in cancer treatment prescription. It is as an effective and reliable mean for significantly re reducing th the ti time to to tre treatm tment t and th the incidence of negati tive side effects ts of unnecessary disease complications and palliative treatments while decreasing considerably the overall healthcare spending in an impactful way. Specifically, from the academic researches and initial tests, the Er Ergano noid is expected to be extraordinarily performing in terms of human ce cells survival rate on a ch chip as a testing bio-environment (70% and potentially 95% with the V.2) and su success ss of tre reatment pre rediction opposing the current slow and ineffective comparable solutions available on the market where only 40% of the cells are able to survive on the chip and not satisfying results are given in more than two month.

The Problems

Without Prejudice & Confidential 3

The effectiveness of cancer treatment depends on many factors, such as the time gap between diagnosis and start of

• treatment. These data are collected by all registries. The effectiveness of treatment also depends on the ty

type of treatment as well as the multidisciplinary care of the patient; the impact of which is more difficult to quantify (1)

Ti Time to treatment Slow process and waiting time negatively impacts the su success r ess rate e of the treatments as co complica cations arises. Early stage disease are likely to have survival that is longer than ‘average’, whereas patients with advanced disease are likely to have survival that is shorter than ‘average’. Ne Negative si side ef effects & & co complica cations Palliative (comfort) treatments such as radiotherapy and generalized solutions as part primary cancer treatments are often used to gain time before the right cure has been prescribed. Unprecise diagnostics leads then to wr wrong t trea eatmen ents and then to perverse effects.

Th Three i interconnected m major p problems

In Increa easi sing co costs on

• n th

the he healthc hcare sec sector

• r

Costs raises with tr trial & error approach not only leads to invasive – sometimes not needed surgery - and non effective therapies but weight on the healthcare ex expenditures and other ne negative ex externalities.

Moreover, it costs LIVES as cancer survival rate is 50% (2)

Without Prejudice & Confidential 4

The ineffective traditional approach

The management of symptoms related to cancer and its treatment is an important part of cancer care, affecting the completion of treatment and quality of life, as well as physical and psycho- logical functioning. . Sid Side effects may occur during active treatment, or months or even years

• later. The most common side effects are

pain, fatigue, and emotional distress.

§ Applying treatment protocols on a human being by injecting a drug without full knowledge

• f consequence

Testing on “mice ce” No No other alt alternat ativ ives Last st reso sorts s § Restart/finish the process with a possibility of complications or death for non-respondents. § Invasive treatments. § 2-3 rounds of chimo-therapy are necessary before

• bserving effects

(2-3 months). § Complication risks lies on the diagnosis. Tr Trial & error testing

+

Succe ccess/Failure of tr treatm tment t Ch Chemotherapy (often

paired with other treatments)

+

Pa Patient hosp spitalization As the patient arrives an initial Biopsy test suggests an area of tissue in the body isn't normal. High risk sk & infect ctiveness Patient disease complications as the right treatment has not been applied in due time. Secondary and adverse effects of multiple treatments.

1 2 3

Tr Traditional approach First diagnosis included bi biopsy is a medical test commonly performed by a surgeon, interventional radiologist, or an interventional cardiologist involving extraction of sample cells or tissues for examination to determine the presence or extent of a disease. The tissue is generally examined unde under a mi micr croscope by by a pa patho hologist, and can also be analyzed chemically.

i. There is a 50% chance the protocol is not going to work ii. A patient could have secondary effects

Complications of the current diagnostic & treatment approach Mostly still ineffective and not time and cost efficient

§

Traditional & wrong treatments leads to side-effects

§

Palliative measures are used to increase life expectancy – is it ethical? Can we do more?

§

No individualized approach In the early 1970’s the median survival time after diagnosis was one year, by 2007 it was six years and by 2011 it was ten years. However, most of the times there is not a complete resolution and patients still need to get further treatments.

Post-treatments & side effects

USP 1: PROBLEM

The criticality of the time to prognosis & treatment

Without Prejudice & Confidential 5

USP 2: PROBLEM

• Protocol 1
• Protocol 2
• Protocol 3
• ….

Current prognosis, diagnosis and treatment processes

Prognosis delays, lab delays, treatment waiting time leads to

irreversible complications

Sometimes it can take a while to get back lab results. This can be even harder to deal with when you’re waiting to get test results to see if it’s cancer or if cancer has come back. It’s scary to find out about a change in blood counts, or a tumor or mass (lump) and not know if it’s cancer. Waiting for these results can be a frightening time, and people can go through some strong emotions, including disbelief, anxiety, fear, anger, and sadness (5)

Early diagnostic: typical waiting time is two weeks Receipt of first treatment following decision: typical waiting time is one month Receipt of first treatment following referral: typical waiting time is 2+ months

Early diagnosis as spotting cancer early is important for improving survival, so it is important that patients with potential cancer symptoms are referred promptly. The speed at which patients receive their first treatment can have a positive outcome on their clinical outcome, so it is important that patients with cancer symptoms are treated promptly. The speed at which patients receive their first treatment can have a positive outcome on their clinical outcome, so it is important that patients with cancer symptoms are treated promptly.

Among the most used protocols (4)

§

Surgery to remove the tumour

§

Radiotherapy

§

Chemotherapy

La Lack of

• f in

indiv ivid idual al Tr Treatments as as current individual tests are performed via fe few selected and pre- approved protocols

Despite a net increase of 20% on average of survival rate, Chemotherapy is currently chosen for cancer patients on Tr Trial & Error basis, without certainty that the co correct treatment is choose. Drug testing via An Animal studies to predict value to human effect is difficult, studies take time and are ex expensive.

Without Prejudice & Confidential 6

§ Biopsy § Testing of medicine on Swiss Medical Union biochip § Recommendation of treatment to the medical doctor § Applying the recommended treatment to the patient § Finish the process of treatment without secondary effects § Results in less than 14 days

Impacts on the healthcare sector

Service provision

§

It is currently ineffective due to op

• per

eration

• nal i

inefficien encies es

§

It generate co collateral expenditures as palliative treatments are used to gain time

§

Treatments are often ineffective due to lac lack of

• f p

patien ent d data which lead to wrong medical decisions

§

Current treatment and diagnostics are expensive and no no inc nclus usive as pricing point do not enable the universal supply – insurance companies struggle to pay less. Sa Savin ing of liv lives Im Impact on

• n t

the h e hea ealthcare s e system em Sw Swis iss Medic ical al Unio ion Ap Approach Test inclusion - from USD 10k per Chemotherapy

USP 3: PROBLEM

$ 2 bn

Savings on Healthcare sector assuming total adoption – our estimations

+40%

Cost-efficiency and bed turnover efficiency – our estimations time to treatment saving time (stage 0- to 1)

• 35%

+60%

Our estimations

Lower Side effects & complication

Our estimations

That leads to more costs 50% 50%

(14)

The Solution: Erganoid - 1™

Without Prejudice & Confidential 7

Er Erganoid – 1™ is a human’s organ biochip specifically designed to increase the accuracy in treatment selection for patient in intensive care. Such will be done without injecting any drugs into the patient on a “trial-and-error” basis and without testing products on animals.

Ex Ex-viv vivo te testing of real patient samples with several proposed treatments. Optimal treatment can be id identifie ified wit ithin in 7 da days, s, without harming the patient unnecessarily.

Qui Quick and nd indi ndividua dual treatme ment

IP IP Protec ection:

• Patent pending PCT/EP2019/070184
• n the whole system: Micro-

bioreactor comprising an organ

• layer. Deposited 26.07.2019.
• Complete use of third party

technology – co confidential.

Tr Trends in cell biology treatment response

Three «Organs» for the «Man-on-the-chip»

Without Prejudice & Confidential 8

Bi Bio-Ch Chip (Polycarbonate pa pane nel fo for Cell fixation):

§

Silicone layer with channels for the circulation of the “medium” representing the human body and organs.

§

Quartz glass slide.

§

Polycarbonate panel for cell fixation.

§

Fittings and tubes for connection to the control unit.

§

Pump system on the chip.

§

Thermo-stating system.

I.

Addressing aggressive metastatic cancers: liver, stomach, kidneys, pancreas, bone marrow, skin, lungs.

Mi Micr cro-Bi Bioreactor (C (CE-Ma Mark rk Cl Class IIa IIa): ):

§

Connecting up to 8 Bio-chips (V2: 50 Bio-Chips) with models of human

• rgans and tissues.

I.

Independent control of experiments.

II.

Touchscreen display and firmware.

III.

Regulators and sensors of vacuum and pressure.

IV.

Thermostatic holder.

V.

Able to connect CO2 lines to work outside the incubator.

So Softwar are:

§

To simulate the activity of various organs at the same time (Reaction of the cell material).

§

To analyze the interaction between the active product and a specific human organ.

I.

The organ will be able to treat and react “live” to the injected product;

II.

The active substance will then be diffused in the circulatory system;

III.

The substance will interact with the other organs and all the effects will also be monitored.

IV.

The results would be transmitted as recommendations for the treatment to the doctor.

Micro-Bioreactor Bio-chip

The «Man-on-the-chip»: the magic

Without Prejudice & Confidential 9

1.

• 1. The organ

an pla late

§

Organ plate hosting human tissues with tumour cell resection in human friendly ecosystem.

§

Organ plate simulating the whole body reaction and circulation with microfluidics and the nutrition plate

§

Cells multiply and continue their natural growth on the chip. 2.

• 2. Testin

ing envir ironment

§

Drugs are added on the chip to simulate the treatments.

§

Monitor the reaction and the effects of the treatment by manipulating it with integrated valve.

§

Contrast liquid and reagents are added in 7-14 days time span to gather the results depending on the requested protocol and cells received. 3.

• 3. Fin

inal al result lts

§

Observation the colour of the cells to evaluate the impacts of the drug through the optical spectroscopy on the sensor plate.

§

A report is generated and sent to the doctor/laborant. Ho How d w does i

• es it w

wor

• rks

De Device samples

Erganoid - 1™ without human tissue Erganoid - 1™ hosting human tissue Erganoid - 1™ operating in series to maximize the testing environment

I n s u r a n c e s Healthcare

Without Prejudice & Confidential 10

Swiss Medical Union approach: USP summary

§ Re Reduction of insurance expenses on cancers (about ¼ of total expenditures) would lead to decreases premiums and increase coverage. § Increase in inclu lusio ion due to financial means. § Increase in po post-tr treatm tment t coverage. § Inputs to contribute to a even more fair Swiss DRG – R50C reimbursement code. § Comprhensive benefit for the all population.

L i v e s

§ 80% ti time sa saving ng for patient treated 14 day-2 months. § 75% cos

• sts sa

saving ngs on treatment selection for clinics. § Higher bed turn-over and increase in ho hospi spital capa pacity. § New data available and te testing environment on which create new treatment and in individ ividual al vac accin ines es. § Increase in treatment effectiveness trough an ac accurate cure selection. § Decrease ti time to tr treatm tment t and increase chances to treat cases at an early detection. § Reduction of in invas asiv ive e an and pallia alliativ ive e treatments – in particular chemotherapy only when required. § Significant reduction of wr wrong tr treatm tments ts. § Increase mo monit itorin ing for chronic cases

Erg Ergano noid - 1™

Business model: clinical practice inclusion and R&D Labs

Without Prejudice & Confidential 11

• Oncology clinics perform test pr

prior each chemotherapy

• Results between 7 days and 2 months depending on the requested protocol

and cells received

• Clinics & Labs may need 2-3

3 Mic icro-bi bioreactor to achieve efficiency and series analysis Gua Guarantee of

• f pr

produc ducts

§

Micro-Bioreactor 5 years

§

Bio-Chips 1 time usage Cu Customer Su Support

§

24/7 International team

• f scientists

§

Individual trainings Mi Micr cro-Bi Bioreactor CHF 25’000 Bi Bio-ch chip CHF 400 One-off payment Recurring revenue Consumables Device Cu Customer support & Tr Training

Cl Clinics & Research Labor

• rator
• ries

Pay-as-you-go Recurring revenue Ad Ad-ho hoc servi vice & SW cu customi mization for labs Individual solutions Hourly Fees

The market: definitions

Without Prejudice & Confidential 12

Global cancer burden The global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. One in 5 men and one in 6 women worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease. Worldwide, the total number of people who are alive within 5 years of a cancer diagnosis, called the 5-year prevalence, is estimated to be 43.8 million (WHO: 2018).

Swiss snapshot (6)

Total populations

8 544 026

Number of new cases

56 506

Number of deaths

18 377

Number of prevalent cases (5-years)

201 542

(7)

Out-of-pocket costs of cancer care often pose a significant financial burden that continues long after initial treatment is complete Global spending on cancer drugs rose at an annual rate (avg. 2014)

+10. 10.3%

No effective treatment solutions leads pharma companies to invest 30% in cancer R&D Global increase of early diagnostics and early intervention but ca capacity issues Non-inclusive health plans and treatments given without diagnostics in developing countries

+60 60%

Worldwide Cancer De Deaths would to 13 million due to lack or treatments, capacity issues and inefficiency

(8) (9) (9) (10) (8) (10)

The market: data & sales orientation

Without Prejudice & Confidential 13 Oncologist in Europe

10’000+

(11)

Oncology facilities in Europe

650+

(11)

Only cancer facilities in Europe

50+

(11)

University hospitals in Europe

700+

Medical faculties in Europe

250+

• f CH hospital

drug expenditures are cancer treatments

21.3%

(11) (12)

§

Insurances reimburse up to 5 chemo-therapies

§

Total treatment cost starting at 250K CHF- Swiss DRG – R50C reimbursement code

§

Every year, more than 35,000 people are diagnosed with cancer

(13)

In Inves estigation

• ns/

s/yea ear

§

Ta Target / suitable Customers

Ø

Re Revenue potential (at 10% Market Share) 100. 100.000+ 000+ drug testin ing st studies

§

3.000 drug testing studies (Swiss based companies: Novartis, Roche, J&J) - Source: ICTRP database 2017, Animal welfare database 2016

Ø

300.000 patient tests 150 150 Mio io Chemo-Th Therapy in init itia iatio ions only ly for Ca Cancer patients

§

6.000 Chemo-Therapies (Swiss Top 5 Oncology clinics) - Source: MedicalXPress 2017

Ø

18.000 tests (each patient 3 tests) 5-200 200 Mode of Actio ion St Studie ies

§

5-200 Mode of Action Studies 30 Mode of Action studies

Ø

35.000 patient tests 5000+ 5000+ Dose-re response te testing

§

1000+ Dose-response testing

Ø

100 patient tests Ph Phar arma- Indus ndustry Hosp Hospitals Cosm smetic- In Industry Chemi mica cal- In Industry

FOCUS

Competitive landscape: by USP

Without Prejudice & Confidential 14

Applicable for several diseases Can be performed at point of care Personalised Medicine “Ready” Process automation Swiss made

Our Team, business advisors and partners

Without Prejudice & Confidential 15 Da Daniil Gol

• lubev – CE

CEO & Founder Public health professional, Academic researcher for HUG, CH

Ad Advisory Board

Dr

• Dr. Dm

Dmitry Sk Skorchelletti - Business Expert, Expert for Roszdravnadzor, FDA Russia Pa Patrick De Debergh - Senior patent Engineer specialised in Microsystems, Micro-nano technologies and micro-optics IP

St Strategic ic par artner for testin ing & product valid alidatio ion

Ma Mari rion Ar Argi gi – CM CMO PR & Communication specialist An Andrey Al Alikimovich – CT CTO Web technologies specialist Ema Emanue nuele Pizzatti CFO Venture Partner, startup coach & advisor

• Dr. Ivan Tretyakov - Business Expert Legal

expert in international expansion

Sc Scie ientif ific ic Boar ard

Pr

• Prof. Alexander To

Tonevitsky - Inventor of the technology, Program Head of the Cellular & Molecular Biotechnologies at the HSE University, Moscow Pr

• Prof. Dr. Med. Udo Schumacher - Director of
• f Anatomy and Experimental Morphology,

University Medical Center Hamburg – Eppendorf, Germany

• Prof. Idris Guessous - Head of Population

Epidemiology, HUG/ CH

initiating research of partners for production

InnoSuisse Project – Swiss Innovation Agency

Without Prejudice & Confidential 16

Ou Our pa partne ners, s, HE HEIG IG-VD VD: Hau Haute Ec Ecole d' d'Ing ngéni nierie et et de de Ges Gestio ion du du Ca Canton Va Vaud

• Dr
• Dr. Ro

Romuald Mo Mosqueron – Professor at HEIG logic and computer architecture, specialized in remote-production, video transmission and smart cameras.

• Mr
• Mr. Fa

Fabien Du Dutoi

• it – Specialist of Data Mining and Analysis
• Dr
• Dr. La

Laura El Elena na Ra Raileanu – Professor at HEIG, Researcher at the Cancer Epidemiology Unit, CHUV (2002-2005)

• Dr
• Dr. Ca

Carlos An Andrés Pe Peña – Professor in computer engineering, leads the Biomedical Applications Axis at the ICT department which belongs to the Health, Engineering and Economics (HEE) group

• Pr
• Prof. Ph

Philippe Po Potty – Professor HE-ARC Medical Devices Group Leader

In InnoSuisse – the Swiss innovation agency is supporting Swiss Medical Union for the development of the V.2 of the MicroBio Reactor:

Organizational Plan – Key Companies

Without Prejudice & Confidential 17

Supplier Supplier Supplier Supplier Supplier Supplier Supplier Supplier Consumables & Disposables Software Integrator Clinics/Hostpitals & Labs End-customer

Downstream Supply Chain Upstream Supply Chain

Production & supply chain coordination Sales – focus DACH

Administration & Logistic

Owned activities Value chain Key supplier

Micro Bio-reactor manufactures Bio-chip manufactures

R&D Finance & Corporate dev. Marketing & BD

Fuct ctions: Microstructuring and combining dielectric coatings with metal or electrically conductive coatings – lab-on-a-chip solutions manufacturers. Co Company ty type: OEM, Hardware Integrators. Distributors

From 2021 – EU + NA

Clients Key partners Production chain

Fuct ctions: Manufacturing of a bioreactor that enable the rapid evaluation cultures at microscale and increase productivity in cell line development Co Company type: OEM, Hardware Integrators. Fuct ctions: For wide clinical technologies IT / SW upgrades for SMU clinical settings. Co Company type: IT developers, SW integrators. Fuct ctions: Manufacturing of a consumables and disposables for single usage as well as wafers and basic chemicals. Co Company type: OEM

Joint-venture – optimal scenario

Without Prejudice & Confidential 18

Do Downstream value chain Up Upstream value ue cha hain

Sw Swis iss Medic ical al Unio ion SA

Jo Joint- or

• r c

co- ma manufact cturi ring / / ve vent nturing agreement nt with Swiss ma manufact cturer( r(s) - ex externalized

Capital Injection for financing operations

First Milestone

Current focus

Second Milestone

Ma Manageme ment SA Long-term vision Di Distribution agreement with di distribut butors and nd / or medi dical co companies - ex externalized Bio-chip manufactures

Su Supply: Flow cells, 3D printing biochips, nano-range lab-on-a-chip components, gratings, integrated electrodes and microchannels & cuvettes, micro-fluids, organ-plate.

TARGET COMPANIES

Micro Bio-reactor manufactures

Su Supply: bio-reactor, wrecks, integrated vacuum+air compressors.

TARGET COMPANIES

Micro Bio-reactor manufactures

Su Supply: Support in comlpention of Swiss Medical Union’s Software.

TARGET COMPANIES

Consumables & Disposables

Su Supply: Single usage consuables.

TARGET COMPANIES Target companies are meant to provide an overview of company capabilities

Achievements to date

Without Prejudice & Confidential 19 § Registration of SMU SA § Incubated at YParc § MVP creation § Collaboration with UKE Hamburg

Q1 2019 Q2 2019

§ Support by HUG § Initial Seed Round § IP - PCT submission § Clinical Validation Start with UKE § Initial Seed Round

Q3 2019

§ Patent submission & CE Mark submission § Accepted at InnoSuisse HEIG VD § Venture Kick stage 1 won § Suvorov prize finalists § Swiss Innovation Challenge finalists

2018

§ Initial testing & concept validation

Q4 2019

§ 1st

st Ca

Capital Raise

§

CE Mark & ISO14485 certification from ElectroSuisse

§

Chip testing at UKE and HUG

§

First customer

§

Capital raise

§

Start interaction with distributors & logistics companies

§

EU Research grants

§

Bring chip success rate at 95%

§

Initiate R&D process for Micro-bioreactor V2 as an InnoSuisse project with HEIG-VD and HE Arc

§

EU Research grants

§

Engage industry validators

§

Agreement with pharma for drug testing

§

Agreement with Labs for overall testing

§

Agreement with hospitals for reactor testing

Objectives for 2020

Swiss Innovation Challenge – Finalists Venture Kick – stage 2 IPIEC2019 – Finalists Seedstars expansion program – Asia Summit 2019 participation Suvorov Prize 2019 – Finalists Websummit – Prize winners for Portugal 2019

Prizes and competitions

Go To Market – strategic elements

Without Prejudice & Confidential 20 R& R&D and Product validation: A. Investigate into market dynamics and deepen into Er Ergano noid - 1™ impacts on healthcare value delivery and saving along with growth opportunities of the market in the years to come to validate product positioning. B. Analysis of key supply know-how elements and availability to negotiate better joint-venture terms. C. Monitor industry trends, opportunities and threats to gain competitive market intelligence and improving key financial metrics to meet financial sustainability requirements. Pr Production: A. Mapping the landscape including qualitative and quantitative research incorporating the impact of economic and non-economic aspects. B. Analysis of key supply know-how elements to negotiate better fore coming venturing terms and to establish a competitive framework to achieving maximum efficiency from med- components manufactures from focused economies. C. Select and securing partners for production able to meet Swiss Medical Union’s starting-up condition and able to establish win-win supplying/co- production agreements able and provide economic value to track to track market trends and disruptions to implement strategies to delay Er Ergano noid - 1™’s maturity time. D. Periodically review organizational structure to maximize company productivity according to the business goals defined in the partnerships and Swiss Medical Union sales strategy re-orientation after market fit and discovery phases once in roll-out and while exploring way to jointly increase

• utcomes and further streamline the production.

Di Distribution A. Further investigate the role of industry validators such as Academic Reviews and lobbying around to gain recognition from (some examples):

§

Journal of Clinical Oncology

§

New England Journal of Medicine

§

The Lancet A. Assess the role of potential labelers to formulate an investment thesis and an appealing ad ad-ho hoc and discounted offering to advertise cooperation with To Top Players to create a story of success and validate the product market fit while discovering further product improvements and R&D inputs to cope with further market demand. Our expectation is to benefit from advisors as facilitators and companies engaged in our ecosystem to facilitate early adoption and testing. The following targets – to be enriched – would work as testing business environments to develop a robust plan to

• rientate the business and to uncover sources of future growth of the company.

B. Validating our initial assumption to focus sales proposition of Er Ergano noid - 1™ on early cancer detection cases (level 0-1) and all the cases where a quick feedback on treatments options is needed – typically very late disease stages. C. Confirming our hypothesis on healthcare impact and clinic saving while improving the ad-hoc selling proposition (i.e. 75% savings for clinics) while educating Oncology clinics to perform tests prior of each chemotherapy to gather useful data and metrics.

In Intial Clinics cs/Hopsi sital

§

HUG

§

CHUV

§

Clinique Genolier

§

Unisspital Zurich

§

Unisspital Basel Laboratories s

§

Edgar Boillat

§

SynLab

§

Argot Labs

Go To Market – Sales orientation

Without Prejudice & Confidential 21

Re Recommender Influ Influen encer er Di Distributor

• rs

Di Direct Sales

Value of partnership in Swiss “ap approver & lab labelin ling clie lients” Selection of brand representatives and recognized de decision n ma makers Ac Accademia & Publication

• ns:

Knowledge relevant to SMU’s USP concept In Industry validators 1st tier manufacturers

Technical Criteria (non-selling) Business Criteria (selling)

Ex Expl ploring ng off-lin line chan annels ls

• Se

Securing sw sweet spots

• Do

Documenting Er Ergano noid’ d’s pe performa manc nce In Initiating

• Ma

Magazine reviews s & op

• pinion
• n

le lead aders

• Bu

Build bridges & Peer-va validation Sp Sponsoring decision makers

• In

Inves est in sales es mater erials

• Ex

Expl ploring ng co-br brandi nding ng/co- ma marketing ng (TBC) Le Leverag agin ing omni-ch channels

• Se

Select client of choice and br brand nd amba mbassado dors

• So

Soft results – br brand nd value ue in increas ase “Market rewards visions” More conscious and value oriented healthcare providers Go mission critical on impact to health-care sectors Responsible innovation Drive sales towards added value See now, buy now Engage approving bodies and brand ambassadors – clients Engage of testimonials & ecosystem players and industry validators

Sales mode Focus Conditions &

• rientation

Strategic Branding vision Sales activity

Focus

Use of funds: CAPEX elements & deal info

Without Prejudice & Confidential 22

Financials: Expected results and EV

Without Prejudice & Confidential 23

Annex I: Bibliography

Without Prejudice & Confidential 24

1 Nicer - https://www.nicer.org/assets/files/Krebs_in_der_Schweiz_e_web.pdf 2 Macmillan - https://www.macmillan.org.uk/documents/aboutus/newsroom/livingaftercancermediancancersurvivaltimes.pdf 3 Cancer.org - https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2019-2021.pdf

• 4. Cancer Research UK - https://www.cancerresearchuk.org/health-professional/cancer-statistics/diagnosis-and-treatment
• 5. Catalyst.nejm.org - https://catalyst.nejm.org/time-to-treatment-cancer-patients/
• 5. Cancer.org - https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis
• 6. GCO- https://gco.iarc.fr/today/data/factsheets/populations/756-switzerland-fact-sheets.pdf
• 7. GCO - http://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf
• 8. Cancer.org - https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2019-2021.pdf
• 9. R Gare - https://rgare.com/knowledge-center/media/articles/global-trends-surviving-cancer-surviving-the-cost-of-cancer-care
• 10. House of Commons UK - https://researchbriefings.parliament.uk/ResearchBriefing/Summary/CDP-2018-0282
• 11. Euro Stat - https://ec.europa.eu/eurostat/statistics-explained/index.php/Cancer_statistics#Cancer_healthcare
• 12. OECD - https://www.oecd.org/switzerland/38868953.pdf
• 13. Nicer -https://www.nicer.org/assets/files/publications/others/krebs_in_der_schweiz_e_web.pdf
• 14. Dcatvci - https://dcatvci.org/5476-strong-growth-for-the-oncology-drug-market

Indust stry related additional readings: s: WHO, World Health Organisation, 2018, PRESS RELEASE N° 263, https://www.who.int/cancer/PRGlobocanFinal.pdf GloboCan http://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf

Without Prejudice & Confidential 25

You should not miss this investment because

We We ca can satisfy a large market ne need.

• d. With the «Man-on-the-Chip» technology, we end «Trial & Error» testing for very sick

patients Ou Our product ct has a cl clear short-te term de developm pment pat

• path. Ready for take-off mid 2020 – including international patent.

In Investment wi will pay pay-bac back withi hin n sh short rt time.

• e. Profitable business with exit possible 2024 once Micro-Bioreactor is

developed (or earlier TBD).

Contacts: Sw Swis iss Medic ical al Unio ion Sa Sarl CH-550.1.183.498-2 c/o Y-Parc SA Rue Galilée 7 - 1400 Yverdon-les-Bains CH-550.1.183.498-2 Da Danil Gol

• lubev

+41 79 630 61 49 dgolubev@medicalunion.swiss Ema Emanue nuele Pizzatti +41 78 924 03 84 epizzatti@medicalunion.swiss

THANK YOU!

Annex I: VC-backed exits – cancer space startups

Without Prejudice & Confidential 26

Annex II: Exit strategy

Without Prejudice & Confidential 27

§ IPO § Strategic Acquisition after CE/FDA clearance or after first market pilots from: § MedTech corporates § Strategic partners Able to significantly contribute to Swiss Medical Union market expansion and adoption. § Buyout after market growth with partnership with quick T-CELL and drug conjugates technology companies.

Ca Cancer space exit valuation

• n

Pos

• ssible scenarios
• s

Annex III: Exit strategy, strategic acquisition

Without Prejudice & Confidential 28

St Strategic ic Buyer Ac Acquisition thesis Substantially evolve previous version of the Er Ergan anoid

• id. The

Improvements in efficiency, in R&D, synthetization processing and Time-To-Market for new products are expected to gain competitive edge. Eventually, it would significantly reduce time and expenditures on animal testing. This cluster may complete their Medical Device Portfolio offering to clinics and laboratories with an innovative solution. Essentially, they would to scale Er Ergan anoid id horizontally and open new markets. Revolutionary innovations in this market are rare, and companies are looking for staying ahead of the trend to stay innovative Especially for Skin-care, improving efficiency of R&D is important. Especially skin-tests take time to be done and often require significant investment For this cluster, an acquisition would potentially unlock value in other verticals. Main development hurdle is Skin-Care. Reducing these will help developing new agents more frequently. Po Potential deal structure Total acquisition Geographical / Licensing TBD

Cosmetics Diagnostics Pharma Exit possible as of 2024 once the Micro-Bioreactor V2 is developed or earlier TBD)

Annex IV: Considerations at scale: Key Financial & strategic metrics

Without Prejudice & Confidential 29

Af After initi tial market t tr tracti tion in CH/DACH (DE and AU would be towards distr tributors) and in case current t exit t goals would be dela layed ed, it t is pl planne anned t d to i invest r resour urces t towar ards ds s shi hifting S ng Swiss M Medi dical al U Uni nion e n entrepr prene neur urial al t to a bus a busine ness gr growth m h mental ality b by f focus using e ng eff ffort rts on:

§

Identifying the major parameters impacting the branding in distribution procedures;

§

Understanding the dynamics of the key segments within the market space of new target countries (Nor Nordics and An Angl glo Saxonian countries) while trying to give an outline on the performance of the market across regions to validate our assumptions and being ready for scale;

§

Detail major factors influencing the sales (drivers, opportunities, industry-specific challenges, and other critical issues). Factors to evaluate while negotiating with distribution partners;

§

Determine geographic breakdown of the market in terms of detailed analysis and impact on sales. Track the competitive landscape

• f distributors in cancer early detection incumbents and new entrants;

§

Consideration about distributors engagement terms, pricing strategies and models for to regional and country level outreach as well as licensors and companies to share production/distributor’s risks;

§

Investigate options around lean structure in processing sales that would allow the management team to focus on ensuring infrastructure readiness for scaling operations outside CH;

§

Explore affiliate marketing partnership.